Windtree Therapeutics Ownership
| WINT Stock | USD 4.06 0.59 17.00% |
Shares in Circulation | First Issued 1995-03-31 | Previous Quarter 575 K | Current Value 887 K | Avarage Shares Outstanding 236.6 K | Quarterly Volatility 845 K |
Windtree |
Windtree Stock Ownership Analysis
The company has Price to Book (P/B) ratio of 0.59. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Windtree Therapeutics recorded a loss per share of 19.03. The entity last dividend was issued on the 29th of April 2020. The firm had 1:18 split on the 22nd of April 2024. Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. Windtree Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. For more information please call Craig Fraser at 215 488 9300 or visit https://windtreetx.com.Besides selling stocks to institutional investors, Windtree Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Windtree Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Windtree Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Windtree Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Windtree Therapeutics Insider Trades History
Less than 1% of Windtree Therapeutics are currently held by insiders. Unlike Windtree Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Windtree Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Windtree Therapeutics' insider trades
Windtree Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Windtree Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Windtree Therapeutics backward and forwards among themselves. Windtree Therapeutics' institutional investor refers to the entity that pools money to purchase Windtree Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-12-31 | 6.0 | Royal Bank Of Canada | 2024-12-31 | 2.0 | Activest Wealth Management | 2024-12-31 | 2.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | Armistice Capital, Llc | 2024-12-31 | 0.0 | Ifp Advisors, Llc | 2024-12-31 | 0.0 | Renaissance Technologies Corp | 2024-12-31 | 119.3 K | Ubs Group Ag | 2024-12-31 | 59.6 K | Geode Capital Management, Llc | 2024-12-31 | 59.2 K | Xtx Topco Ltd | 2024-12-31 | 19.5 K |
Windtree Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Windtree Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Windtree Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Windtree Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Windtree Therapeutics Outstanding Bonds
Windtree Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Windtree Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Windtree bonds can be classified according to their maturity, which is the date when Windtree Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Windtree Therapeutics Corporate Filings
8K | 18th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
S1 | 14th of February 2025 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
F3 | 14th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 30th of December 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.